IL154102A0 - Urocortin proteins and uses thereof - Google Patents
Urocortin proteins and uses thereofInfo
- Publication number
- IL154102A0 IL154102A0 IL15410201A IL15410201A IL154102A0 IL 154102 A0 IL154102 A0 IL 154102A0 IL 15410201 A IL15410201 A IL 15410201A IL 15410201 A IL15410201 A IL 15410201A IL 154102 A0 IL154102 A0 IL 154102A0
- Authority
- IL
- Israel
- Prior art keywords
- ucn
- crf
- urp
- urocortin
- human
- Prior art date
Links
- 108010059705 Urocortins Proteins 0.000 title abstract 6
- 102000005630 Urocortins Human genes 0.000 title abstract 6
- 239000000777 urocortin Substances 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 101000658084 Homo sapiens U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Proteins 0.000 abstract 3
- 101000841331 Homo sapiens Urotensin-2B Proteins 0.000 abstract 3
- 102000057476 human UTS2B Human genes 0.000 abstract 3
- 108091005470 CRHR2 Proteins 0.000 abstract 2
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 abstract 2
- 108090000189 Neuropeptides Proteins 0.000 abstract 2
- 101710166315 U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Proteins 0.000 abstract 2
- 102100029789 Urocortin-2 Human genes 0.000 abstract 2
- 230000033228 biological regulation Effects 0.000 abstract 2
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 abstract 1
- 101710198652 Corticotropin-releasing factor receptor 1 Proteins 0.000 abstract 1
- 101000939391 Homo sapiens Urocortin Proteins 0.000 abstract 1
- 101000939386 Mus musculus Urocortin-2 Proteins 0.000 abstract 1
- 102000003797 Neuropeptides Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 102000053170 human UCN Human genes 0.000 abstract 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- ZEBBPGHOLWPSGI-KPLDDXDLSA-N urocortin ii Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CS)C(N)=O)CC1=CN=CN1 ZEBBPGHOLWPSGI-KPLDDXDLSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22325500P | 2000-08-04 | 2000-08-04 | |
| US27396901P | 2001-03-07 | 2001-03-07 | |
| PCT/US2001/023976 WO2002012307A1 (en) | 2000-08-04 | 2001-07-31 | Urocortin proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL154102A0 true IL154102A0 (en) | 2003-07-31 |
Family
ID=26917597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15410201A IL154102A0 (en) | 2000-08-04 | 2001-07-31 | Urocortin proteins and uses thereof |
| IL154102A IL154102A (en) | 2000-08-04 | 2003-01-23 | Urocortin-related peptide, dna encoding same and pharmaceutical composition comprising same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL154102A IL154102A (en) | 2000-08-04 | 2003-01-23 | Urocortin-related peptide, dna encoding same and pharmaceutical composition comprising same |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US6838274B2 (xx) |
| EP (1) | EP1305334B1 (xx) |
| JP (1) | JP4873825B2 (xx) |
| KR (1) | KR100879232B1 (xx) |
| CN (1) | CN1484650B (xx) |
| AT (1) | ATE408622T1 (xx) |
| AU (2) | AU2001284683B2 (xx) |
| CA (1) | CA2418144C (xx) |
| CY (1) | CY1110424T1 (xx) |
| DE (1) | DE60135850D1 (xx) |
| DK (1) | DK1305334T3 (xx) |
| ES (1) | ES2313978T3 (xx) |
| IL (2) | IL154102A0 (xx) |
| PT (1) | PT1305334E (xx) |
| RU (1) | RU2278871C2 (xx) |
| WO (1) | WO2002012307A1 (xx) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100879232B1 (ko) * | 2000-08-04 | 2009-01-20 | 리서치 디벨럽먼트 파운데이션 | 우로코르틴 단백질 및 이를 포함하는 약제학적 조성물 |
| US20020082409A1 (en) * | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US6812210B2 (en) * | 2001-03-15 | 2004-11-02 | Research Development Foundation | Urocortin-III and uses thereof |
| US7192923B2 (en) | 2002-01-16 | 2007-03-20 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| WO2008047241A2 (en) * | 2006-10-16 | 2008-04-24 | Conjuchem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| EP2522351B1 (en) | 2007-06-13 | 2017-09-06 | Research Development Foundation | Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
| US20100184680A1 (en) * | 2007-09-11 | 2010-07-22 | Dorian Bevec | Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| CA2699083A1 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| EP2470560B1 (en) * | 2009-08-28 | 2015-06-10 | Research Development Foundation | Urocortin 2 analogs and uses thereof |
| US9314506B2 (en) | 2011-10-24 | 2016-04-19 | Research Development Foundation | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors |
| IN2014DN06789A (xx) * | 2012-02-14 | 2015-05-22 | Univ California | |
| JOP20170153A1 (ar) | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| CN110826145B (zh) * | 2019-09-09 | 2020-08-28 | 西安工业大学 | 基于超启发式马氏链进化的汽车多参数运行工况设计方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002504802A (ja) | 1995-06-13 | 2002-02-12 | ザ ソルク インスティテュート フォア バイオロジカル スタディース | ウロコルチンペプチド |
| KR100879232B1 (ko) * | 2000-08-04 | 2009-01-20 | 리서치 디벨럽먼트 파운데이션 | 우로코르틴 단백질 및 이를 포함하는 약제학적 조성물 |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
-
2001
- 2001-07-31 KR KR1020037001559A patent/KR100879232B1/ko active IP Right Grant
- 2001-07-31 AU AU2001284683A patent/AU2001284683B2/en not_active Ceased
- 2001-07-31 JP JP2002518278A patent/JP4873825B2/ja not_active Expired - Fee Related
- 2001-07-31 US US09/919,473 patent/US6838274B2/en not_active Expired - Lifetime
- 2001-07-31 DE DE60135850T patent/DE60135850D1/de not_active Expired - Lifetime
- 2001-07-31 PT PT01963759T patent/PT1305334E/pt unknown
- 2001-07-31 AU AU8468301A patent/AU8468301A/xx active Pending
- 2001-07-31 DK DK01963759T patent/DK1305334T3/da active
- 2001-07-31 IL IL15410201A patent/IL154102A0/xx unknown
- 2001-07-31 RU RU2003105897/13A patent/RU2278871C2/ru not_active IP Right Cessation
- 2001-07-31 AT AT01963759T patent/ATE408622T1/de active
- 2001-07-31 WO PCT/US2001/023976 patent/WO2002012307A1/en active IP Right Grant
- 2001-07-31 CN CN018157831A patent/CN1484650B/zh not_active Expired - Fee Related
- 2001-07-31 EP EP01963759A patent/EP1305334B1/en not_active Expired - Lifetime
- 2001-07-31 CA CA2418144A patent/CA2418144C/en not_active Expired - Fee Related
- 2001-07-31 ES ES01963759T patent/ES2313978T3/es not_active Expired - Lifetime
-
2003
- 2003-01-23 IL IL154102A patent/IL154102A/en not_active IP Right Cessation
-
2004
- 2004-10-25 US US10/973,092 patent/US7223846B2/en not_active Expired - Lifetime
-
2007
- 2007-04-05 US US11/784,317 patent/US7638607B2/en not_active Expired - Fee Related
-
2008
- 2008-12-17 CY CY20081101461T patent/CY1110424T1/el unknown
-
2009
- 2009-12-07 US US12/632,715 patent/US8044025B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001284683B2 (en) | 2006-04-27 |
| EP1305334B1 (en) | 2008-09-17 |
| DK1305334T3 (da) | 2009-02-02 |
| CN1484650A (zh) | 2004-03-24 |
| US8044025B2 (en) | 2011-10-25 |
| JP2004505640A (ja) | 2004-02-26 |
| US7638607B2 (en) | 2009-12-29 |
| DE60135850D1 (de) | 2008-10-30 |
| US20100168021A1 (en) | 2010-07-01 |
| EP1305334A4 (en) | 2005-03-23 |
| IL154102A (en) | 2010-12-30 |
| CY1110424T1 (el) | 2015-04-29 |
| AU8468301A (en) | 2002-02-18 |
| RU2278871C2 (ru) | 2006-06-27 |
| PT1305334E (pt) | 2008-12-30 |
| RU2003105897A (ru) | 2005-01-20 |
| ATE408622T1 (de) | 2008-10-15 |
| US7223846B2 (en) | 2007-05-29 |
| CA2418144C (en) | 2013-06-18 |
| CN1484650B (zh) | 2012-12-12 |
| KR20030074589A (ko) | 2003-09-19 |
| EP1305334A1 (en) | 2003-05-02 |
| US6838274B2 (en) | 2005-01-04 |
| WO2002012307A1 (en) | 2002-02-14 |
| US20020127221A1 (en) | 2002-09-12 |
| ES2313978T3 (es) | 2009-03-16 |
| CA2418144A1 (en) | 2002-02-14 |
| US20070191592A1 (en) | 2007-08-16 |
| JP4873825B2 (ja) | 2012-02-08 |
| KR100879232B1 (ko) | 2009-01-20 |
| US20050191650A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110424T1 (el) | Πρωτεϊνες ουροκορτινης και χρησεις αυτων | |
| KR102302392B1 (ko) | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 | |
| Zhao et al. | The purification and partial amino acid sequence of a polypeptide from the glutelin fraction of rice grains; homology to pea legumin | |
| CA2055963C (en) | Chimeric fibroblast growth factor | |
| KASAI et al. | Determination of the complete amino acid sequence of calmodulin (phenylalanine-rich acidic protein II) from bovine brain | |
| Graham et al. | Complete amino acid sequence of soybean leaf P21: similarity to the thaumatin-like polypeptides | |
| CA2438851A1 (en) | Interleukin-18 mutants, their production and use | |
| Crabb et al. | Characterization of multiple forms of prostatropin (prostate epithelial cell growth factor) from bovine brain | |
| HU215434B (hu) | Eljárás interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, vektorok és gazdasejtek előállítására | |
| CA2461443A1 (en) | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use | |
| Schmelzer et al. | Biochemical characterization of recombinant human nerve growth factor | |
| Minchiotti et al. | Two alloalbumins with identical electrophoretic mobility are produced by differently charged amino acid substitutions | |
| Browning et al. | Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers | |
| Gayler et al. | Biosynthesis, cDNA and amino acid sequences of a precursor of conglutin δ, a sulphur-rich protein from Lupinus angustifolius | |
| Araki et al. | The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure | |
| Harper et al. | Human class 1 heparin-binding growth factor: structure and homology to bovine acidic brain fibroblast growth factor | |
| ATE287952T1 (de) | Humanes thymosin beta 15 gen,protein und dessen verwendungen | |
| Leszyk et al. | Amino acid sequence of a 15 kilodalton actin-binding fragment of turkey gizzard caldesmon: Similarity with dystrophin, tropomysin and the tropomyosin-binding region of troponin T | |
| Lundwall et al. | Chemical characterization of cyanogen bromide fragments from the β‐chain of human complement factor C3 | |
| GIUFRIDA et al. | The amino-acid sequence of two isoforms of α-lactalbumin from donkey (Equus asinus) milk is identical | |
| Uegaki et al. | Characterization of the DNA binding domain of the mouse IRF-2 protein | |
| Shuck et al. | Cloning, heterologous expression and characterization of murine interleukin 1 receptor antagonist protein | |
| Lai et al. | Two novel Bv8-like peptides from skin secretions of the toad Bombina maxima | |
| Wang et al. | Purification of heparin‐binding protein HBp17 and identification of HBp17 heparin binding site | |
| Brandt et al. | The amino acid sequence of wheat histone H2B (2) A core histone with a novel repetitive N‐terminal extension |